← Leaderboards
J Herbert Patterson
University Of North Carolina Chapel Hill
$1,587,288
Attributed
$1,587,288
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,587,288 · 4
By mechanism
M01$1,587,288 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Kirkwood F Adams$4,990,072
- Alicja Bielawska$7,829,586
- Kathleen C Light$8,355,143
- Michael J Golding$676,049
- Karon J Dawkins$1,352,098
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHeart FailureAntihypertensive AgentsCardiovascular PharmacologyCytochrome P450Drug InteractionsEnzyme ActivityEnzyme InhibitorsFluoxetineIsozymesPharmacokineticsStereochemistryStereoisomerBeta Antiadrenergic AgentGender DifferenceHealth Care Cost /FinancingHeart Disorder ChemotherapyOutcomes ResearchDisease /Disorder EtiologyHuman Therapy EvaluationQuality Of LifeRacial /Ethnic DifferenceHeart Ventricle
Grant awards (12)
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACO AMONG HIV-1 MEN AND WOMEN$19,125
M01 · FY2006 · RR · contact PI
Effects of Beta-Adrenergic Receptor Polymorphisms on Metoprolol in Heart Failure$8,208
M01 · FY2004 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$190,747
M01 · FY2002 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$294,555
M01 · FY2001 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$190,747
M01 · FY2001 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$294,555
M01 · FY2000 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$294,555
M01 · FY2000 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$294,555
M01 · FY2000 · RR
EFFECT OF FLUOXETINE ON STEADY STATE CARVEDILOL STEROSPECIFIC PHARMACOKINETICS$241
M01 · FY2000 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$0
M01 · FY2000 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$0
M01 · FY2000 · RR
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST)$0
M01 · FY2000 · RR